IFNG and neoplasm: First pre-clinical studies of the combination of these antibodies to achieve blockade of both CTLA-4 and PD-1 showed increased tumor infiltration by CD4+ and CD8+ T-cells, enhanced IFNγ and TNFα production, and reduced amounts of Tregs (91).